Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.46 |
| ▸ | FPR2 | P25090 | 6/20 | 0.42 |
| ▸ | FPR3 | P25089 | 3/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6670085 | 0.83 | OPRM1 (0.37) | THRB | |
| SCHEMBL6668708 | 0.80 | CNR1 (0.41) | USP30PTPN2PTPN1PTPN6 | |
| SCHEMBL12518728 | 0.79 | OPRM1 (0.53) | USP30GPR119PDE4BKDM4EMAPT | |
| SCHEMBL6670724 | 0.79 | USP30 (0.42) | USP30GPR119 | |
| SCHEMBL25170898 | 0.78 | HDAC1 (0.45) | USP30GPR119MAPT | |
| SCHEMBL30368816 | 0.78 | HDAC1 (0.45) | USP30GPR119MAPT | |
| SCHEMBL2363625 | 0.78 | USP30 (0.39) | USP30GPR119PDE4BKDM4EMAPT | |
| SCHEMBL6672883 | 0.78 | MGLL (0.42) | USP30GPR119 | |
| SCHEMBL9936121 | 0.77 | GPR119 (0.47) | USP30FPR2FPR3GPR119PTPN2 | |
| SCHEMBL6220238 | 0.76 | USP30 (0.46) | USP30FPR2FPR3GPR119PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214815-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2004-10-28 | — | — | US | disclosed |
| US-6762191-B2 | TREATING DISEASES FOR MODULATING OF 5-HT ACTIVITY, CENTRAL NERVOUS SYSTEM DISORDERS, ANXIETY, OBESITY, DEPRESSION, OR A STRESS-RELATED DISEASE | PHARMACIA & UPJOHN COMPANY | 2004-07-13 | — | — | US | disclosed |
| EP-1404679-A2 | (HETERO)ARYL SUBSTITUTED BENZOFURANS AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030050304-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2003-03-13 | — | — | US | disclosed |
| WO-2003004501-A2 | (HETERO) ARYL SUBSTITUTED BENZOFURANS AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214815-A1 | Therapeutic compounds | HTR5A, HTR6, HTR1A | USP30 4736/4885FPR2 179/4885FPR3 96/4885 |
| US-20030050304-A1 | Therapeutic compounds | HTR5A, HTR6, HTR1A | USP30 4736/4885FPR2 179/4885FPR3 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.